These data propose CP as a marker for aggressive/refractory RCC and suggest PAX8 activity as relevant for RCC progression and aggressiveness supporting the notion of PAX8 as a potential therapeutic target for RCC. The gene discussed is PAX8; the disease is renal cell carcinoma.